Grover Conference on Risk Factors in Pulmonary Hypertension
Grover Conference on Risk Factors in Pulmonary Hypertension
批准号:
8130165
负责人:
KAREN A. FAGAN
金额:
$3.0万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2012-06-30
关键词:
AgeBasic ScienceBlood CirculationBlood VesselsCellular biologyCessation of lifeClinicClinicalClinical ManagementCommunitiesComplexDevelopmentDiagnosisDiagnosticDisciplineDiseaseEndocrinologyEnvironmental Risk FactorEpigenetic ProcessEstrogen MetabolismFDA approvedFemaleGenderGeneticGenetic RiskGonadal Steroid HormonesHeartHeart failureLearningLife ExpectancyLungLung diseasesMalignant NeoplasmsMeta-AnalysisMinorityMolecularMolecular BiologyMutationObesityPatientsPenetrancePharmacologyPhysiologyProgressive DiseasePublishingPulmonary CirculationPulmonary HypertensionPulmonary artery structureRandomized Controlled TrialsReportingResearchResearch PersonnelRisk FactorsRoleScientistSenior ScientistSeriesSymptomsTherapeuticTranslatingTranslational ResearchTranslationsWomanbone morphogenetic protein receptorsdesigndrug developmenthemodynamicslecturesmeetingsmembermutation carriernovelnovel therapeutic interventionposterspractical applicationprematureproductivity losspulmonary arterial hypertensionrespiratorysymposium
中文摘要
描述(申请人提供):肺动脉高压(PAH)是一种进行性肺血管疾病,导致右心衰竭和死亡。特发性和家族性PAH(分别为IPAH和FPAH)的平均确诊年龄为35岁,如果不治疗,中位生存期为2.8年。在至少70%的FPAH患者中发现了骨形态发生蛋白受体2(BMPR2)的突变。然而,这些BMPR2突变的外显率为10-20%,这表明疾病的表达需要遗传和/或环境修饰物。此外,女性在FPAH患者中的比例明显偏高。这两种现象都没有得到充分的解释,本次会议将回顾和讨论最近的研究,以确定影响疾病外显的主要因素。寻找肺动脉高压(PAH)治疗方法的基础研究成果正在紧张和持续中,这突显了转化性研究的必要性,该研究可以弥合实验室发现和临床领域的实际应用之间的差距。因此,对于基础和临床领域的研究人员来说,在诸如格罗弗会议这样的重点论坛上会面是很重要的。在过去的十年中,PAH药物开发的进展集中在可能导致女性外显性增加的因素以及BMPR2突变携带者疾病表达所需的基因和/或环境修饰物。这些包括雌激素代谢、肥胖、新的内源性血管活性因子和与BMPR2上位相互作用的新的遗传位点。本次大会的演讲和海报演示将回顾这一快速发展的领域。还将讨论遗传和环境风险因素对患者对当前和新兴疗法的反应性的影响。2011年格罗弗会议汇集了遗传学、生理学、药理学、内分泌学等基础研究领域的专家,以及处理药物开发和PAH临床管理的临床方法。特邀演讲者包括ATS肺循环和呼吸细胞及分子生物学大会的成员,他们代表了积极研究PAH潜在细胞和分子机制的研究小组。我们还邀请了其他相关学科的主讲人,因为PAH具有复杂的病理生物学,从肥胖、表观遗传学和癌症等其他领域可以学到重要的经验教训。自1984年成立以来,2011年格罗弗会议将是该系列的第15次,是历史最长的肺循环会议。今天,它仍然是肺血管功能的主要会议。
英文摘要
DESCRIPTION (provided by applicant): Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vasculature resulting in right heart failure and death. Idiopathic and familial forms of PAH (iPAH and fPAH respectively) have a mean age at diagnosis of 35 years and a median survival of 2.8 years if untreated. Mutations in the bone morphogenetic protein receptor 2 (BMPR2) have been identified in at least 70% of FPAH patients. However, the penetrance of these BMPR2 mutations is 10- 20%, suggesting that genetic and/or environmental modifiers are required for disease expression. In addition, females are significantly over-represented amongst FPAH patients. Neither of these phenomena have been adequately explained and this conference will review and discuss recent research with a view to determining the major factors influencing disease penetrance. Basic research findings are intense and ongoing to find treatments for pulmonary arterial hypertension (PAH), highlighting the need for translational research which bridges the gap between lab bench discoveries and practical applications in the clinical realm. As such, it is important for researchers from both basic and clinical fields to meet in focused forums such as the Grover Conference. In the past decade, advances in PAH drug development have centered on factors that may be responsible for the increased penetrance in females and genetic and/or environmental modifiers that are required for disease expression in BMPR2 mutation carriers. These include estrogen metabolism, obesity, novel endogenous vasoactive factors and novel genetic loci interacting epistatically with BMPR2. Talks and poster presentations at this conference will review this rapidly developing field. The impact of genetic and environmental risk factors on the responsiveness of patients to current and emerging therapies will also be discussed. The 2011 Grover Conference brings together experts in the basic research fields of genetics, physiology, pharmacology, endocrinology, as well as clinical approaches dealing with drug development and the clinical management of PAH. Invited speakers include members of the ATS Pulmonary Circulation and Respiratory Cell and Molecular Biology Assemblies at the ATS representing active research groups studying the underlying cellular and molecular mechanisms of PAH. We have also invited key-note speakers from other relevant disciplines as PAH has a complex pathobiology and there are important lessons to be learned from other fields such as obesity, epigenetics, and cancer. Since its inauguration in 1984, the 2011 Grover Conference will be the 15th in this series, representing the longest-standing conference on the pulmonary circulation. Today it remains the principal conference for pulmonary vascular function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CORE--ANIMAL
-
批准号:7371915
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2007
-
负责人:KAREN A. FAGAN
-
依托单位:
2006 Grover Conference on the Pulmonary Circulation - Rho Family GTPases
-
批准号:7112851
-
项目类别:
-
资助金额:$2.9万
-
财政年份:2006
-
负责人:KAREN A. FAGAN
-
依托单位:
Genetics of Pulmonary Hypertension in Mice
-
批准号:7005837
-
项目类别:
-
资助金额:$16.64万
-
财政年份:2005
-
负责人:KAREN A. FAGAN
-
依托单位:
CORE--ANIMAL
-
批准号:6728400
-
项目类别:
-
资助金额:$8.09万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Pulmonary Hypertension following Intermittent Hypoxia
-
批准号:6577629
-
项目类别:
-
资助金额:$28.34万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Pulmonary Hypertension following Intermittent Hypoxia
-
批准号:6760901
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Pulmonary Hypertension following Intermittent Hypoxia
-
批准号:7599807
-
项目类别:
-
资助金额:$19.27万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Pulmonary Hypertension following Intermittent Hypoxia
-
批准号:6906520
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Pulmonary Hypertension following Intermittent Hypoxia
-
批准号:7099499
-
项目类别:
-
资助金额:$11.54万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Effects of BMPRII Mutations in Pulmonary Hypertension
-
批准号:7099567
-
项目类别:
-
资助金额:$44.84万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
Effects of BMPRII Mutations in Pulmonary Hypertension
-
批准号:7599806
-
项目类别:
-
资助金额:$5.94万
-
财政年份:2003
-
负责人:KAREN A. FAGAN
-
依托单位:
PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
-
批准号:6182798
-
项目类别:
-
资助金额:$12.0万
-
财政年份:1998
-
负责人:KAREN A. FAGAN
-
依托单位:
PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
-
批准号:6388478
-
项目类别:
-
资助金额:$12.0万
-
财政年份:1998
-
负责人:KAREN A. FAGAN
-
依托单位:
PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
-
批准号:6526985
-
项目类别:
-
资助金额:$12.0万
-
财政年份:1998
-
负责人:KAREN A. FAGAN
-
依托单位:
PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
-
批准号:2680787
-
项目类别:
-
资助金额:$8.64万
-
财政年份:1998
-
负责人:KAREN A. FAGAN
-
依托单位:
PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
-
批准号:6043696
-
项目类别:
-
资助金额:$12.0万
-
财政年份:1998
-
负责人:KAREN A. FAGAN
-
依托单位:
CORE--ANIMAL
-
批准号:7049542
-
项目类别:
-
资助金额:$9.02万
-
财政年份:--
-
负责人:KAREN A. FAGAN
-
依托单位:
CORE--ANIMAL
-
批准号:7198044
-
项目类别:
-
资助金额:$8.29万
-
财政年份:--
-
负责人:KAREN A. FAGAN
-
依托单位:
海外基金